American Academy of Pain Medicine
Update: Community Data for Naloxone Spray Shows ‘Real-World’ Efficacy
A survey conducted with police and community organizations describing real-world experiences and outcomes using the ...
MARCH 17, 2017
Study Finds Genetic Variants Associated With Risk for Fibromyalgia
A retrospective analysis has found two genetic polymorphisms with a statistically significant association with ...
JUNE 2, 2016
Combination Dexamethasone Reduces Pain, Enhances Nerve Block Duration Compared With Systemic Dex Alone
The combination of systemic and perineural dexamethasone improved pain scores and decreased opioid requirements ...
MAY 31, 2016
Up to Half of Fibromyalgia Patients Have Hard Evidence of Small-Fiber Polyneuropathy
This is the first firm evidence of a biological mechanism for fibromyalgia, a disease that was often thought to be ...
MAY 27, 2016
Epidural Steroid Injections May Reduce Spending for Patients With Low Back Pain
ESIs were associated with total health care spending decreases of 16.4%, 7.56% and 4.67% for radiculitis, sciatica ...
MAY 23, 2016
Stratification Tool for Opioid Risk Mitigation Helps Predict and Prevent Adverse Events
The Stratification Tool for Opioid Risk Mitigation is a safer, more effective approach to managing pain, with and ...
MAY 9, 2016
Low-Dose Naltrexone May Provide Relief for Fibromyalgia Patients
Up to 50% of patients receiving low-dose naltrexone have shown significant improvement in overall ...
MAY 3, 2016
Naldemedine Improves Opioid-Induced Constipation in Patients With Chronic Noncancer Pain
Naldemedine treatment for 12 weeks significantly relieved opioid-induced constipation compared with placebo, as ...
APRIL 27, 2016
AAPM Endorses National Pain Strategy
The American Academy of Pain Medicine has endorsed the Department of Health & Human Services’ National ...
APRIL 4, 2016